Watch LIVE the focusIR May Investor webinar with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIp Group Regulatory News (IPO)

Share Price Information for Ip Group (IPO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 50.70
Bid: 50.30
Ask: 50.50
Change: 1.00 (2.01%)
Spread: 0.20 (0.398%)
Open: 49.50
High: 51.00
Low: 49.50
Prev. Close: 49.70
IPO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Joint venture with China Everbright to launch fund

28 May 2021 10:00

RNS Number : 1087A
IP Group PLC
28 May 2021
 

FOR RELEASE ON

28 May 2021

 

IP Group plc forms joint venture with China Everbright Ltd to

launch a £167m* (RMB1.5bn) fund in China

 

IP Group plc (LSE:IPO) ("IP Group" or "the Group"), the developer of intellectual property-based businesses, is delighted to announce a joint venture with China Everbright Limited (HKG:0165) in Hong Kong to launch a fund in China aimed at providing growth capital to China-based subsidiaries of IP Group's UK portfolio companies.

 

The fund, which can only invest in entities incorporated in the PRC such as the China subsidiaries of overseas companies or joint venture structures, is expected to achieve a first close of RMB500m (c.£56 million*) later this year and increase to RMB1.5bn (c. £167 million*) within the next three years.

 

Aimed at supporting high-growth companies wanting to establish a presence in China, the fund will deploy no less than 40% of the capital to IP Group plc portfolio companies with the balance available to non-IP Group deep technology companies. 

 

Alan Aubrey, Chief Executive of IP Group plc, said: "We are delighted to partner with one of the most renowned asset management firms in Greater China to support the growth of our portfolio companies in the region. This joint venture is consistent with our stated strategy of working with high-quality partners to provide our companies with access to expertise, network and capital."

 

Dr Wei Zhao, Chairman of China Everbright, said: "China Everbright has always been committed to the cultivation of high-growth technology businesses with its unique cross-border approach. We look forward to working with IP Group plc to enable world-class science and technology to make contributions to humanity."

The fund will be managed from the IP Group side by Dr Lewis Zhenyu Liu, Managing Director of IP Group Greater China and Managing Partner of IPG-CEL China Ventures, and Joyce Dan Xie, Managing Director of IP Group Greater China and Partner of IPG-CEL China Ventures. China Everbright is IP Group's exclusive partner in the RMB fund management business in China.

Dr Lewis Zhenyu Liu, Managing Director of IP Group Greater China and Managing Partner of IPG-CEL China Ventures, said: "The joint venture is dedicated to providing both financial and strategic support to deep technology businesses with unparalleled growth opportunities in one of the world's most dynamic economies."

* GBP equivalents calculated using 9 CNY/GBP.

For more information, please contact:

 

IP Group plc

www.ipgroupplc.com

Greg Smith, Chief Financial OfficerLiz Vaughan-Adams, Communications

Dr Lewis Zhenyu LiuJoyce Dan Xie

+44 (0) 20 7444 0050+44 (0) 20 7444 0062/+44 (0) 7979 853802

lewis.liu@ipgroupgc.com

joyce.xie@ipgroupgc.com

Charlotte Street Partners

David Gaffney

+44 (0) 7854 609998

Andrew Wilson

+44 (0) 7810 636995

 

Notes for editors

 

About IP Group

 

IP Group is a leading intellectual property commercialisation company which focuses on evolving great ideas, mainly from its partner universities, into world-changing businesses. The Group has pioneered a unique approach to developing these ideas and the resulting businesses by providing access to business building expertise, capital (through its 100%-owned FCA-authorised subsidiaries IP Capital and Parkwalk Advisors), networks, recruitment and business support. IP Group has a strong track record of success and its portfolio comprises holdings in early-stage to mature businesses across life sciences and technology. IP Group is listed on the Main Market of the London Stock Exchange under the code IPO.

 

For more information, please visit our website at www.ipgroupplc.com.

 

About China Everbright Limited

China Everbright Limited was established in Hong Kong in 1997 and is China's leading cross-border investment and asset management company. Its parent company is China Everbright Group. Everbright manages private equity funds, venture capital funds, industry funds, mezzanine funds, parent funds, fixed income and equity funds. Everbright utilises its strong private capital and cultivates a number of high-growth-potential enterprises together with its investors.

 

ENDS

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRADKOBKFBKDCPB
Date   Source Headline
3rd Jan 20198:56 amRNSHolding(s) in Company
11th Dec 20187:00 amRNSWaveOptics completes £20.0m funding round
10th Dec 20187:05 amRNSAvacta signs deal with LG Chem worth up to $310m
4th Dec 20185:49 pmRNSPortfolio co Ceres finalises deal with Weichai
3rd Dec 20187:00 amRNSUltrahaptics completes £35.0m funding round
31st Oct 20185:52 pmRNSDirector Declaration
18th Oct 20182:00 pmRNSAmgen invests £50m in Oxford Nanopore Technologies
15th Oct 20187:00 amRNSPortfolio co Garrison completes £22.9m financing
8th Oct 20187:07 amRNSPortfolio co Diurnal headline data for Chronocort
19th Sep 20189:51 amRNSDirector/PDMR Shareholding
17th Sep 20184:58 pmRNSDirector/PDMR Shareholding
17th Sep 20184:38 pmRNSDirector/PDMR Shareholding
17th Sep 201812:12 pmRNSDirector/PDMR Shareholding
17th Sep 20187:00 amRNSAppointment of Chairman; Board changes
31st Aug 20189:55 amRNSHolding(s) in Company
30th Aug 20187:00 amRNSGenomics announces Vertex leads £25m financing
29th Aug 20186:29 pmRNSIP Group plc -SAYE scheme
21st Aug 20187:06 amRNSCeres signs agreement with Bosch; £9m investment
10th Aug 20187:11 amRNSArtios Pharma completes £65m financing
31st Jul 20188:40 amRNSTR-1: NOTIFICATION
25th Jul 20187:00 amRNSHalf-yearly results
6th Jul 20187:00 amRNSNotification of Major Interest in Shares
4th Jul 20182:40 pmRNSCeres Power announces £20m fundraising
2nd Jul 20187:00 amRNSHolding(s) in Company
27th Jun 20187:30 amRNSCarisma announces $53m Series A funding round
27th Jun 20187:00 amRNSNotification of Major Interest in Shares
22nd Jun 201810:00 amRNSAppointment of Joint Broker
18th Jun 20181:37 pmRNSResult of AGM
7th Jun 20186:00 pmRNSHolding(s) in Company
6th Jun 20189:26 amRNSMicrobiotica signs collaboration worth up to $534m
16th May 201810:49 amRNSPortfolio co Ceres partners with Weichai Power
16th May 20187:00 amRNSNotice of AGM; Annual Report
11th May 20187:00 amRNSDirector/PDMR Shareholding
10th May 20186:18 pmRNSDirector/PDMR Shareholding
9th May 20185:31 pmRNSDirector share purchase
4th May 20187:00 amRNSBoard changes
30th Apr 20187:00 amRNSTotal Voting Rights
16th Apr 20185:45 pmRNSDirector/PDMR Shareholding
12th Apr 20189:19 amRNSEnterprise Therapeutics raises £29m
5th Apr 20181:12 pmRNSIP Group plc - Issue of Equity
4th Apr 201811:46 amRNSIP Group plc - Director/PDMR share purchase
29th Mar 20187:00 amRNSFinal Results
20th Mar 20187:00 amRNSOxford Nanopore announces £100m fundraising
17th Jan 201811:53 amRNSHolding(s) in Company
10th Jan 20189:12 amRNSHolding(s) in Company
2nd Jan 20187:00 amRNSTotal Voting Rights
18th Dec 201710:15 amRNSAutifony signs Eur627.5m agreement with BI
15th Dec 201712:50 pmRNSDiurnal receives positive CHMP opinion for Alkindi
14th Dec 20174:48 pmRNSDirectorate Change
13th Dec 20172:27 pmRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.